

<p>Informazione Regolamentata n. 0957-65-2026</p>	<p>Data/Ora Inizio Diffusione 20 Maggio 2026 11:14:46</p>	<p>Euronext Milan</p>
---	---	-----------------------

Societa' : DIASORIN

Utenza - referente : DIASORINN02 - Ragazzo Eugenia

Tipologia : 2.2

Data/Ora Ricezione : 20 Maggio 2026 11:14:46

Data/Ora Inizio Diffusione : 20 Maggio 2026 11:14:46

Oggetto : Diasorin Board of Directors approves the 2026-2030 Business Plan

Testo del comunicato

Vedi allegato

DIASORIN BOARD OF DIRECTORS APPROVES THE 2026-2030 BUSINESS PLAN

“The 2026-2030 Plan reflects our ambition to strengthen Diasorin’s positioning as a leader in specialty diagnostics, leveraging the Group’s different business lines through the introduction of new tests and cutting-edge technological platforms”, commented Carlo Rosa, CEO of Diasorin. “We will continue to invest in our specialty products and strategic partnerships to capture growth opportunities in high-value clinical segments, while maintaining a strong focus on long-term value creation”.

GUIDANCE 2026-2030 AT CONSTANT EXCHANGE RATES¹

- **REVENUE GROWTH:**
 - 2026: BETWEEN +5% AND +6% VS PY, CONFIRMING 2026 GUIDANCE
 - 2026-2030: BETWEEN +6% AND +8% (CAGR)
- **ADJUSTED² EBITDA³ MARGIN:**
 - 2026: 32% - 33%, CONFIRMING 2026 GUIDANCE
 - 2030: 34% - 35%
- **FREE CASH FLOW⁴:**
 - 2027-2030 CUMULATIVE FCF: ~1 €/BLN

GROWTH DRIVERS

- **IMMUNODIAGNOSTICS:** SPECIALTY MENU EXPANSION IN NEW HIGH-VALUE CLINICAL AREAS (AUTOIMMUNITY, HYPERTENSION, GASTRO-INTESTINAL INFECTIONS), CONTINUOUS GROWTH IN THE U.S. HOSPITALS, AND RESPONSE TO HIGHER PRODUCTIVITY AND TESTING VOLUMES WITH THE NEW LIAISON XL
- **MOLECULAR DIAGNOSTICS:** LAUNCH OF LIAISON NES FOR NEAR-PATIENT TESTING, COMPLETION OF THE MENU AND COMMERCIAL STRENGTHENING OF LIAISON PLEX IN THE MULTIPLEXING SEGMENT, AND EXPANSION OF THE SPECIALTY MENU ON THE LIAISON MDX AND LIAISON MDX PLUS PLATFORMS
- **LICENSED TECHNOLOGIES:** STRENGTHENING OF KEY PARTNERSHIPS AND NEW OPPORTUNITIES IN THE PHARMACEUTICAL SECTOR

Bresso (Milan, Italy), May 20, 2026 - The Board of Directors of Diasorin S.p.A. (FTSE MIB: DIA) examined and approved today the 2026-2030 Business Plan, confirming the Company’s focus on executing strategic projects and expanding to new high-value clinical areas.

Following the Luminex acquisition, Diasorin benefits from a more balanced and diversified portfolio of products and technologies, capable of capturing new growth trajectories, and a much greater critical mass and presence in the U.S., the largest IVD market globally and the most rewarding one for innovation.

The 2026-2030 Plan expands and reinforces Diasorin’s highly specialized portfolio and supports the commercial execution of the molecular multiplexing and point-of-care platforms, within a market driven by structural trends such as population aging, increasing prevalence of chronic diseases, and growing adoption of precision medicine. The growth strategy underpinning the new plan is based on Diasorin’s distinctive positioning as a “diagnostic specialist,” with a focused approach targeting specific clinical areas where the Group’s technologies and commercial presence can generate sustainable value for customers and shareholders.

Below is an overview of the main strategies and programs across the three business lines.

¹ In order to allow comparability across years, all financials’ data have been restated at constant exchange rate (with regards to the U.S. dollar: 1.20 USD per EUR).

² Without non-recurring Luminex integration/restructuring costs.

³ EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group’s operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group’s operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous with that adopted by other operators and/or groups and therefore may not be comparable.

⁴ Free Cash Flow equals net cash flow generated from operating activities including uses for investment and before payment of interest and acquisitions of companies and businesses.

1. IMMUNODIAGNOSTICS - Leading in specialty, high-value clinical areas

Diasorin will continue to build on its leadership in specialty immunodiagnostics by leveraging a differentiated positioning centered on high-value clinical areas, an increasingly broad specialty test menu, and the strength of the LIAISON brand.

The strategy is designed to respond to evolving laboratory needs, particularly the growing demand for automation and efficiency, while remaining suited to laboratories of different sizes and operating models.

Diasorin aims to further strengthen its platform offering and continue expanding its specialty portfolio, supporting laboratories through the ongoing evolution and consolidation of testing environments, reinforcing its unique positioning as a specialty player and delivering innovative tests with high clinical value.

The Group plans to expand its leadership in specialty, high-value clinical segments, with **over 20 new assays focused on autoimmunity, hypertension, gastrointestinal testing, and infectious diseases**, further strengthening Diasorin's differentiated positioning in specialty diagnostics.

The **new LIAISON XL analyzer**, specifically designed in response to the increasing laboratory consolidation trend, will enable laboratories to enhance productivity and manage higher testing volumes.

Finally, Diasorin plans to develop its **complementary diagnostics** capabilities to support precision medicine and expand the clinical relevance of its immunodiagnostic portfolio.

2. MOLECULAR DIAGNOSTICS - Winning where speed, flexibility and ease of use matter most

The Group is building a differentiated positioning by combining targeted testing, multiplex capabilities, and near-patient diagnostic solutions, enabling laboratories and healthcare providers to deliver faster and more tailored clinical decision-making while maintaining high standards of accuracy and efficiency.

Within this framework, Diasorin will drive growth through the expansion of the **LIAISON NES** platform, particularly in decentralized settings and selected clinical areas such as respiratory testing and women's health, addressing the increasing demand for rapid, near-patient testing solutions with laboratory-level quality.

In parallel, the Group will continue to strengthen its presence in multiplex diagnostics through the **LIAISON PLEX** platform, expanding its offering and providing flexible and fully customizable panels, aligned with evolving clinical and workflow requirements.

Finally, Diasorin will further enhance its specialty low-plex menu on its **LIAISON MDX** and **LIAISON MDX Plus** platforms, through the development of high clinical value tests with limited competition.

3. LICENSED TECHNOLOGIES (LTG) - Enabling innovation for strategic partners

The LTG segment will continue to play a strategic role as an enabler of innovation and growth by providing technologies and solutions to strategic partners across life sciences and diagnostics.

Through this model, the Company will further expand its reach to academic and pharmaceutical customers, creating value through long-term partnerships and new business development opportunities.

This positioning is supported by a highly diversified customer base across diagnostics players, life science operators, and pharmaceutical companies, enabling a combination of a stable and profitable core business in Diagnostics with innovation-driven growth engines in research, drug discovery, and vaccine development.

expectations with regard to its financial results and other aspects of the Group's operations and strategies. Readers of this Press Release should not place undue reliance on such forward-looking statements, as final results may differ significantly from those contained in the above-mentioned forecasts owing to a number of factors.

This press release is available to the public at the registered office of the Company and is also published on the Company's website (www.diasorin.com) under the section "Investors - Financial Corner - Press Releases" and on the authorized storage system named eMarket STORAGE at www.emarketstorage.com.

2026 INVESTOR DAY: VIDEO STREAMING ON DIASORIN.COM WEBSITE

Diasorin management will present the new Business Plan to the financial community in a dedicated event starting at 2:00 p.m. CEST, 1:00 p.m. BST, 8:00 a.m. EDT on May 20, 2026.

The event will be available for video streaming on the Group website at the following link: [Investor Day 2026 | Diasorin](#).

The supporting slides will be made available prior to the beginning of the event at the same link and on the authorized storage system named eMarket STORAGE at www.emarketstorage.com.

A recording and transcript of the video conference will be made available after the end of the event at the same link as the presentation.

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing, and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

For additional information, please contact:

INVESTOR RELATIONS

Riccardo Fava

Corporate Vice President Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com

Fine Comunicato n.0957-65-2026

Numero di Pagine: 5